| clinical trial | Q30612 |
| P3098 | ClinicalTrials.gov ID | NCT01419535 |
| P6099 | clinical trial phase | phase I clinical trial | Q5452194 |
| phase II clinical trial | Q42824440 | ||
| P17 | country | United States of America | Q30 |
| P582 | end time | 2017-11-29 | |
| P921 | main subject | adrenal gland hyperfunction | Q4684750 |
| P4135 | maximum age | 70 | |
| P1050 | medical condition | glucose intolerance | Q2661464 |
| P2899 | minimum age | 35 | |
| P1132 | number of participants | 63 | |
| P4844 | research intervention | mifepristone | Q411240 |
| P6153 | research site | National Institutes of Health | Q390551 |
| P859 | sponsor | Eunice Kennedy Shriver National Institute of Child Health and Human Development | Q5409765 |
| P580 | start time | 2011-08-17 | |
| P8363 | study type | interventional study | Q78089383 |
| P1476 | title | Effects of the Glucocorticoid Antagonist, Mifepristone, on Glucose Intolerance in Obese and Overweight Individuals |
Search more.